SCHEMBL4100095

SCHEMBL4100095

O=C(O)CCCCCOC1CCCCO1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
PMP22 Q01453 1/20 0.39
EPHX1 P07099 1/20 0.38
KDM4C Q9H3R0 3/20 0.37
KDM5A P29375 3/20 0.37
PHF8 Q9UPP1 3/20 0.37
KDM2A Q9Y2K7 3/20 0.37
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
KDM4A O75164 1/20 0.36
TBXA2R P21731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118077 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL1532127 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL27200192 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL10518204 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL29172381 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL6526800 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL11577255 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL29148468 1.00 MEN1 (0.59) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL24776345 0.95 MEN1 (0.57) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL31615036 0.92 KMT2A (0.52) MEN1KMT2ALMNATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182737-B1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-07-03 EP disclosed
EP-4182737-B1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-07-03 EP disclosed
CN-118256591-A Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-06-28 CN disclosed
CN-118184532-A Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same 中外制药株式会社 2024-06-14 CN disclosed
CN-113454058-B Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same 中外制药株式会社 2024-03-22 CN disclosed
CN-110869544-B Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-03-08 CN disclosed
US-20230273455-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273455-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
WO-2022012799-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2022-01-20 WO disclosed
US-20090221442-A1 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS XENOPORT, INC. (US) 2009-09-03 US disclosed
US-20090221442-A1 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS XENOPORT, INC. (US) 2009-09-03 US disclosed
US-7413536-B1 Substrates and screening methods for transport proteins XENOPORT, INC. (US) 2008-08-19 US disclosed
EP-1212619-B1 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS XENOPORT INC (US) 2007-05-23 EP disclosed
EP-1212619-A4 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS XENOPORT INC (US) 2004-12-08 EP disclosed
WO-2001020331-A9 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS XENOPORT INC (US) 2002-10-03 WO disclosed
EP-1212619-A1 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS Xenoport, Inc. (US) 2002-06-12 EP disclosed
WO-2001020331-A1 SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS XENOPORT, INC. (US) 2001-03-22 WO disclosed
EP-0270234-A2 Renin inhibitors PFIZER INC. (US) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230273456-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6D, PDE6A MEN1 3047/4885KMT2A 3838/4885ALDH1A1 277/4885
US-20230273455-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6A, PDE6D MEN1 3042/4885KMT2A 4011/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.